These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 24118636)

  • 41. Hepatitis E should be a global public health priority: recommendations for improving surveillance and prevention.
    Kirkwood CD; Dobscha KR; Steele AD
    Expert Rev Vaccines; 2020 Dec; 19(12):1129-1140. PubMed ID: 33441054
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunogenicity and efficacy of a bacterially expressed HEV ORF3 peptide, assessed by experimental infection of primates.
    Ma H; Song X; Harrison TJ; Li R; Huang G; Zhang H; Kong W; Wang Y
    Arch Virol; 2009; 154(10):1641-8. PubMed ID: 19763777
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Challenge studies in Rhesus monkeys immunized with candidate hepatitis E vaccines: DNA, DNA-prime-protein-boost and DNA-protein encapsulated in liposomes.
    Arankalle VA; Lole KS; Deshmukh TM; Srivastava S; Shaligram US
    Vaccine; 2009 Feb; 27(7):1032-9. PubMed ID: 19095027
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Protective role of humoral immune responses during an outbreak of hepatitis E in Egypt.
    Shata MT; Daef EA; Zaki ME; Abdelwahab SF; Marzuuk NM; Sobhy M; Rafaat M; Abdelbaki L; Nafeh MA; Hashem M; El-Kamary SS; Shardell MD; Mikhail NN; Strickland GT; Sherman KE
    Trans R Soc Trop Med Hyg; 2012 Oct; 106(10):613-8. PubMed ID: 22938992
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A truncated ORF2 protein contains the most immunogenic site on ORF2: antibody responses to non-vaccine sequences following challenge of vaccinated and non-vaccinated macaques with hepatitis E virus.
    Zhou YH; Purcell RH; Emerson SU
    Vaccine; 2005 May; 23(24):3157-65. PubMed ID: 15837215
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hepatitis E vaccine: not a moment too soon.
    Holmberg SD
    Lancet; 2010 Sep; 376(9744):849-51. PubMed ID: 20728933
    [No Abstract]   [Full Text] [Related]  

  • 47. Protective immunity against HEV.
    Huang SJ; Liu XH; Zhang J; Ng MH
    Curr Opin Virol; 2014 Apr; 5():1-6. PubMed ID: 24835679
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunogenicity and protective efficacy of a vaccine prepared from 53 kDa truncated hepatitis E virus capsid protein expressed in insect cells.
    Zhang M; Emerson SU; Nguyen H; Engle RE; Govindarajan S; Gerin JL; Purcell RH
    Vaccine; 2001 Dec; 20(5-6):853-7. PubMed ID: 11738749
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hepatitis: Hepatitis E vaccination--is HEV 239 the breakthrough?
    Wedemeyer H; Pischke S
    Nat Rev Gastroenterol Hepatol; 2011 Jan; 8(1):8-10. PubMed ID: 21212772
    [No Abstract]   [Full Text] [Related]  

  • 50. Hepatitis E vaccine candidate harboring a non-particulate immunogen of E2 fused with CRM197 fragment A.
    Wang K; Zhou L; Zhang X; Song C; Chen T; Li J; Zheng M; Wang Y; Zheng Q; Zheng Z; Yu H; Wu T; Gu Y; Zhang J; Zhao Q; Li S; Xia N
    Antiviral Res; 2019 Apr; 164():154-161. PubMed ID: 30802475
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Immunogenicity of experimentally combined hepatitis A and hepatitis E vaccine at different dosage ratio].
    Dong C; Dai X; Meng JH
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Feb; 23(2):130-3. PubMed ID: 17286906
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The development of a recombinant hepatitis E vaccine HEV 239.
    Li SW; Zhao Q; Wu T; Chen S; Zhang J; Xia NS
    Hum Vaccin Immunother; 2015; 11(4):908-14. PubMed ID: 25714510
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recombinant vaccines for hepatitis E.
    Emerson SU; Purcell RH
    Trends Mol Med; 2001 Oct; 7(10):462-6. PubMed ID: 11597521
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunogenicity and safety of an accelerated hepatitis E vaccination schedule in healthy adults: a randomized, controlled, open-label, phase IV trial.
    Chen Z; Lin S; Duan J; Luo Y; Wang S; Gan Z; Yi H; Wu T; Huang S; Zhang Q; Lv H
    Clin Microbiol Infect; 2019 Sep; 25(9):1133-1139. PubMed ID: 30711651
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of the protective effects of a nanogel-based vaccine against rabbit hepatitis E virus.
    Park BJ; Ahn HS; Han SH; Go HJ; Lee JB; Park SY; Song CS; Lee SW; Paik HJ; Choi YK; Choi IS
    Vaccine; 2019 Sep; 37(40):5972-5978. PubMed ID: 31455586
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Seroprevalence of antibodies to hepatitis E virus in two large communities in Havana, Cuba.
    Villalba MC; Guan M; Pérez A; Corredor MB; Frometa SS; Moreno AG; Hu WP; Howard T; Lay LA; Anderson D
    Trans R Soc Trop Med Hyg; 2010 Dec; 104(12):772-6. PubMed ID: 20870260
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Epidemiology of hepatitis E: current status.
    Aggarwal R; Naik S
    J Gastroenterol Hepatol; 2009 Sep; 24(9):1484-93. PubMed ID: 19686410
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The immuno-protect study of a hepatitis E virus ORF2 peptide expressed in E. coli].
    Ge S; Zhang J; Huang G; Pang S; Zhou K; Xia N
    Wei Sheng Wu Xue Bao; 2003 Feb; 43(1):35-42. PubMed ID: 16276869
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hepatitis E vaccines: progress and prospects.
    Worm HC; Wirnsberger G
    Drugs; 2004; 64(14):1517-31. PubMed ID: 15233590
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prophylactic Hepatitis E Vaccine.
    Zhang J; Zhao Q; Xia N
    Adv Exp Med Biol; 2016; 948():223-246. PubMed ID: 27738988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.